1. Introduction {#sec1-jcm-08-00932}
===============

Osteoporosis and cardiovascular diseases (CVD) are the major causes of mortality and morbidity in the elderly \[[@B1-jcm-08-00932]\]. Evidence has shown that both osteoporosis and CVD share similar pathophysiology and risk factors; thus, patients with osteoporosis are at higher risk for development of major CVD, such as ischemic heart disease and stroke, compared with the general population \[[@B1-jcm-08-00932],[@B2-jcm-08-00932]\]. A link between fracture, low bone mineral density (BMD), and vascular calcification has been proposed in patients with osteoporosis, and all were associated with increased risk of cardiovascular mortality \[[@B3-jcm-08-00932],[@B4-jcm-08-00932]\]. Furthermore, moderate to severe renal insufficiency was associated with increased risk of fracture and decreased BMD \[[@B5-jcm-08-00932],[@B6-jcm-08-00932]\].

Renal insufficiency is independently associated with increased risk of cardiovascular events. Patients with chronic kidney disease (CKD) are at 2 to 16 times higher risk of CVD, compared with patients with normal estimated glomerular filtration rate (eGFR) \[[@B7-jcm-08-00932]\]. Vascular calcification has been proven as a characteristic change in the vessels of CKD, and is associated with increased risk of cardiovascular mortality and CKD progression \[[@B8-jcm-08-00932]\]. The prevalence of vascular calcification in CKD patients has been reported to be 47% to 92% \[[@B9-jcm-08-00932]\]. Controlling abnormalities in serum levels of phosphorus, calcium, vitamin D, and parathyroid hormone has been recommended to prevent the progression of vascular calcification and cardiovascular morbidity and mortality in patients with CKD \[[@B10-jcm-08-00932]\].

The mechanism of vascular calcification is complex, and it involves the interaction of various signaling pathways \[[@B11-jcm-08-00932]\]. Recent studies revealed that osteoporosis and vascular calcification may share common pathogenetic mechanisms involving bone morphogenetic proteins and the osteoprotegerin (OPG)/receptor activator of nuclear factor-ĸB (RANK)/RANK Ligand (RANKL) pathway \[[@B3-jcm-08-00932]\]. RANKL is a member of the tumor necrosis factor superfamily \[[@B12-jcm-08-00932]\], which plays a key role in bone metabolism by stimulating osteoclast formation, activation, and survival \[[@B13-jcm-08-00932],[@B14-jcm-08-00932]\]. Research has shown that RANKL also plays an important role in the progression of atherosclerosis and vascular calcification \[[@B15-jcm-08-00932]\]. Low level of serum RANKL is also associated with an increased risk of CVD in older women and men \[[@B16-jcm-08-00932]\].

Denosumab is a fully human monoclonal antibody that acts as an OPG mimicker directed against the receptor activator of RANKL. By blocking the binding of RANKL to RANK, denosumab decreases the number and activity of osteoclasts, decreases bone resorption, and increases BMD \[[@B14-jcm-08-00932]\]. In an animal study, denosumab inhibits aortic calcium deposition and prevents bone loss following glucocorticoid exposure in human RANKL knock-in mice \[[@B17-jcm-08-00932]\]. In the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial, a randomized double-blinded trial, denosumab improves BMD and reduces fracture risk in elderly patients (60--90 years old) with an eGFR ≥ 15 mL/min/1.73 m^2^ \[[@B18-jcm-08-00932]\]. For all these reasons, we hypothesized that denosumab may play a role in reducing cardiovascular events and renal function progression through protection against BMD loss and slow progression of vascular calcification \[[@B19-jcm-08-00932],[@B20-jcm-08-00932]\].

Although evidence shows that denosumab prevents fractures in patients with osteoporosis, limited information is available regarding its effects on CVD risks and renal function progression. The present study aimed to assess the effects of denosumab on CVD prevention and renal function in osteoporotic patients, compared to those of alendronate, a bisphosphonate agent and the first-line treatment for osteoporosis. As alendronate acts as an anti-resorptive agent via different mechanism from denosumab \[[@B21-jcm-08-00932],[@B22-jcm-08-00932]\] and had been used in many large randomize control trials \[[@B19-jcm-08-00932],[@B20-jcm-08-00932]\], it is rational to compare denosumab to alendronate.

2. Materials and Methods {#sec2-jcm-08-00932}
========================

2.1. Study Design and Study Cohort {#sec2dot1-jcm-08-00932}
----------------------------------

This was a retrospective cohort study using the Chang Gung Research Database (CGRD), which is an electronic health record dataset derived from a group of Chang Gung Memorial Hospitals (CGMH) in Taiwan. CGMH is the largest medical center in Taiwan that provides approximately 10%--12% of the healthcare services of the Taiwan national health insurance (NHI) program \[[@B23-jcm-08-00932]\]. The Taiwan NHI program is a compulsory, single-payer health insurance program that covers over 99% of Taiwan's entire population \[[@B24-jcm-08-00932]\]. The CGRD contains detailed diagnosis, prescription, and laboratory test results from emergency department in both in- and outpatient settings. The study was approved by the Institutional Review Boards of the Chang Gung Medical Foundation at Taoyun, Taiwan (permit number: 201800313B0).

Patients aged 20--89 years at the time of initiation of denosumab or alendronate between 1 January 2005 and 31 December 2017 were included in the study, and only patients having ≥1-year admission records before treatment initiation were included in the study. To assess cardiovascular health and renal outcomes, patients were excluded for lack of baseline serum creatinine (SCr) value or having preexisting medical history of chronic dialysis, kidney transplantation, myocardial infarction, congestive heart failure, ischemic stroke, and cancer. Patients receiving procedures for cardiovascular diseases, including coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI), were also identified before treatment initiation and excluded from analyses. Further, patients without any admission records or SCr (or eGFR) values in their follow-up were excluded ([Figure 1](#jcm-08-00932-f001){ref-type="fig"}). Operational definitions and codes for disease conditions and procedures are available in [Table S1](#app1-jcm-08-00932){ref-type="app"}.

2.2. Comparison Groups {#sec2dot2-jcm-08-00932}
----------------------

Patients were classified as the denosumab or alendronate group based on the initial prescription of study medications in out- or inpatient settings. New users of denosumab were identified as patients who never had alendronate within 365 days at baseline period, and the earliest date of denosumab prescribed was defined as the index date. Same criteria were applied for new users of alendronate without prior denosumab treatment.

To minimize potential selection bias, 1:1 propensity score matching (PSM) without replacement was employed to establish matched comparison groups. To adjust for time-varying treatment exposure, that is, patients in the denosumab group switched to alendronate or vice versa during the follow-up period, outcome event was censored upon treatment switch.

2.3. Outcomes {#sec2dot3-jcm-08-00932}
-------------

The incidence of the composite of major CVD, including myocardial infarction, congestive heart failure, and ischemic stroke, was assessed based on hospital discharge diagnoses. Individual outcomes of composite CVD were also analyzed. Renal outcomes were assessed by the mean changes in eGFR from baseline and by incident of eGFR decline ≥30% of baseline. eGFR was assessed every 6 months using the Modification of Diet in Renal Disease (MDRD) equation (175 × SCr − 1.154 × age − 0.203 × 0.742 (if female), mL/min/1.73 m^2^) \[[@B25-jcm-08-00932]\]; operational definition of individual study outcome is available as a [Supplementary Material (Table S1)](#app1-jcm-08-00932){ref-type="app"}.

2.4. Study Covariates {#sec2dot4-jcm-08-00932}
---------------------

Baseline variables considered in the analyses included patient's demographics; comorbid conditions, including items in the Charlson comorbidity index (CCI) and cardiovascular disease risk associated with preexisting hyperlipidemia; procedures of CABG and PCI; and prior medication use: Anti-thrombotic agents (anti-coagulants, anti-platelets), lipid-lowering agents, glucose-lowering agents, antihypertensive agents and other osteoporosis therapy other than study drugs. Prior use of medication with ≥28 days of supply was identified ≤365 days before the index date. Concomitant use of these medications with ≥28 days of supply was identified between the index date and the earliest date of event of interest.

Because the occurrence of acute kidney injury (AKI) is associated with deterioration of renal function, AKI defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria was assessed during follow-up period \[[@B26-jcm-08-00932]\]. Operational definitions of disease conditions and medications uses are available as [Supplementary Material (Table S1)](#app1-jcm-08-00932){ref-type="app"}.

Medication adherence of denosumab (60 mg/mL/syringe, one unit per 6 months) was classified by the number of syringes in the follow-up, namely as \<60% vs. ≥60% medication possession rate (MPR) in every half-year period (e.g., 3 doses/2 years (=expected 4 doses) = 75%). The MPR of alendronate (alendronate 70 mg/tab, alendronate-cholecalciferol 70 mg--70 mcg/tab, one unit per week) in the follow-up was calculated in a 7-day interval over the follow-up period.

2.5. Statistical Analysis {#sec2dot5-jcm-08-00932}
-------------------------

Descriptive statistical analysis results of continuous variables were reported as mean and standard deviation (SD) or median and interquartile range (IQR: 25th, 75th percentile), and data were summarized as n (%) for categorical variables in the study cohort. Comparisons between groups were performed using the Pearson Chi-square test for categorical variables and the Student t-tests for continuous variables.

Propensity score was calculated using logistic regression to model the probability of receipt of denosumab (or alendronate) as a function of patient characteristics in the baseline period, including sex, age at index date, year of treatment initiation, individual CCI conditions, and hyperlipidemia \[[@B27-jcm-08-00932]\]. Standardized mean difference was used to measure covariate balance, and a value of \>0.1 indicated meaningful imbalance after PSM \[[@B28-jcm-08-00932]\].

All patients were followed up from the index date until outcome of interest, death, loss to follow up, or the latest date in the dataset (31 December 2017), whichever came first. Among patients that switched therapy, active treatment was censored at the time of switching. Time to CVD endpoint was analyzed using Kaplan--Meier with log-rank tests. Cox proportional hazard regression was employed for composite incident cardiovascular events and individual cardiovascular event.

Stratified analyses by MPR ≥60% (vs. \<60%) and baseline eGFR ≥60 (vs. \<60) mL/min/1.73 m^2^ were performed to assess the heterogenous effects of denosumab and alendronate. These factors were known to be associated with cardiovascular morbidity and renal outcomes. A two-sided *p*-value of \<0.05 was considered statistically significant. All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA).

3. Results {#sec3-jcm-08-00932}
==========

3.1. Patient Characteristics {#sec3dot1-jcm-08-00932}
----------------------------

A total of 48,391 adult osteoporotic patients receiving alendronate or denosumab were identified, 16,419 of them met the inclusion criteria (denosumab: 3536 patients, alendronate: 12,883 patients) ([Figure 1](#jcm-08-00932-f001){ref-type="fig"}). The mean age of all patients was 69.6 years, and 79.4% of the patients were female. Compared with patients initiated with alendronate, those initiated with denosumab had slightly lower eGFR (77.01 ± 26.47 vs. 72.13 ± 30.57 mL/min/1.73 m^2^) and had more history of dementia, peptic ulcer, diabetes, hypertension, hyperlipidemia, and renal disease ([Table 1](#jcm-08-00932-t001){ref-type="table"}).

In the 1:1 PSM cohort, 5046 denosumab and alendronate-matched pairs were analyzed over a 5-year follow-up period. The baseline characteristics were well balanced in the matched groups and are presented in [Table 1](#jcm-08-00932-t001){ref-type="table"}. There were 2128 (84.34%) patients who adhered with alendronate and 2462 (97.58%) who adhered with denosumab. During the follow-up period, most patients were concomitantly administered medications for hypertension, followed by medications for hyperlipidemia, thrombotic prevention, and diabetes; the frequency of these medications was similar between the denosumab and alendronate groups ([Table 1](#jcm-08-00932-t001){ref-type="table"}). On the contrary, more patients in the alendronate group were concomitantly treated with other osteoporosis therapy than in the denosumab group (9.79% vs. 5.31%, respectively; *p* \< 0.0001) ([Table S2](#app1-jcm-08-00932){ref-type="app"}).

3.2. CVD Incidence {#sec3dot2-jcm-08-00932}
------------------

During the 5-year follow-up period, the incident of CVD was 7.97% (*n* = 201) and 6.74% (*n* = 170) in the denosumab and alendronate groups, respectively. The event with the highest rate was ischemic stroke (4.84%), followed by congestive heart failure (2.58%) and myocardial infarction (1.01%). [Table 2](#jcm-08-00932-t002){ref-type="table"} lists the incidence of composite and individual CVD events in all patients, stratified by MPR. Cumulative incidence of composite CVD was similar between patients in the denosumab and alendronate groups after the 5-year follow-up ([Figure 2](#jcm-08-00932-f002){ref-type="fig"}a; log-rank test, *p* = 0.3743). However, among patients with MPR ≥60%, disease incidence was significantly lower in the denosumab group than in the alendronate group (9.08% vs. 10.3%, respectively) ([Figure 2](#jcm-08-00932-f002){ref-type="fig"}b; log-rank test, *p* = 0.0028). In patients with MPR \<60%, denosumab and alendronate (6.01% vs. 5.48%) showed no difference in CVD incidence ([Figure 2](#jcm-08-00932-f002){ref-type="fig"}c); log-rank test, *p* = 0.8605).

Regarding adjustment for baseline characteristics, use of concomitant medications, and occurrence of AKI, there was a trend toward significant difference in patients with MPR ≥60%. Patients treated with denosumab had a lower risk of developing CVD than those treated with alendronate (AHR 0.74; 95% CI 0.55 to 0.99; *p* = 0.0493) ([Table 3](#jcm-08-00932-t003){ref-type="table"}). Among patients with MPR ≥60%, those treated with denosumab, compared with those treated with alendronate, revealed lower risk of myocardial infarction development (AHR 0.42; 95%CI, 0.18--0.97; *p* = 0.0415), with AHR of 0.72 (95%CI, 0.5--1.04; *p* = 0.0805) for ischemic stroke and 0.74 (95%CI, 0.44--1.24; *p* = 0.2534) for congestive heart failure. Among patients with MPR ≥60%, baseline comorbidities and prior medication uses were closed between groups, except for higher renal, liver diseases and connective tissue disease in the alendronate group ([Table S3](#app1-jcm-08-00932){ref-type="app"}).

3.3. Renal Outcomes {#sec3dot3-jcm-08-00932}
-------------------

Kidney function decreased in both groups during the 5-year period. Patients in the denosumab group had lower eGFR at the 5th year than those in the alendronate group (62.16 ± 31.99 vs. 73.36 ± 33.55 mL/min/1.73 m^2^, respectively) ([Figure S1](#app1-jcm-08-00932){ref-type="app"}). The median decline in eGFR from baseline was of 0.71 mL/min/1.73 m^2^ per year (IQR, −3.41, 4.90) and 0.38 mL/min/1.73 m^2^ per year (IQR, −3.30, 4.90) in the denosumab and alendronate groups, respectively.

The incidence of eGFR decline ≥30% of baseline was 10.4% in the matched cohort, 11.97% in the denosumab group, and 10.19% in the alendronate group (*p* = 0.0436) ([Table 4](#jcm-08-00932-t004){ref-type="table"}). There was no significant difference in cumulative probability of eGFR decline ≥30% of baseline during the 5-year period between the groups (log-rank test, *p* = 0.1794) ([Figure 3](#jcm-08-00932-f003){ref-type="fig"}a). However, patients in the denosumab group showed higher cumulative event rate of eGFR decline ≥30% when baseline renal eGFR \<60 mL/min/1.73 m^2^ (log-rank test, *p* = 0.0005) ([Figure 3](#jcm-08-00932-f003){ref-type="fig"}b).

Denosumab treatment was associated with significantly higher risk of eGFR decline ≥30% than alendronate treatment, when stratified by AKI occurrence (AHR: 1.53; 95% CI 1.09--2.17; *p* = 0.0154), male (AHR: 1.78; 95%CI 1.13--2.80; *p* = 0.0132), and baseline eGFR \<60 mL/min/1.73 m^2^ (AHR 1.50; 95%CI 1.09--2.07; *p* = 0.0132); adjusted for baseline characteristics and use of concomitant medications ([Figure 4](#jcm-08-00932-f004){ref-type="fig"}).

4. Discussion {#sec4-jcm-08-00932}
=============

In the present study, denosumab and alendronate treatments revealed no difference in CVD incidence in the 5-year period. However, in patients with MPR ≥60%, denosumab treatment was associated with lower risk of myocardial infraction development. On the contrary, denosumab treatment, compared with alendronate therapy, had a trend toward poorer renal outcome in males and in patients with poor renal function at baseline and AKI episodes.

The OPG/ RANK/RANKL system has been proposed to mediate both bone remodeling and vascular calcification \[[@B29-jcm-08-00932]\]. Although many previous studies had reported that OPG is a risk factor for progressive atherosclerosis and cardiovascular disease \[[@B30-jcm-08-00932],[@B31-jcm-08-00932]\], the role of RANKL in the pathological mechanisms of CVD remains unclear. RANKL had been detected in thrombus materials at the site of plaque rupture in human coronary arteries \[[@B32-jcm-08-00932]\], but not in normal vasculature \[[@B33-jcm-08-00932]\]. Besides, lower serum RANKL level was associated with increased cardiovascular risk in patients with ischemic heart disease \[[@B34-jcm-08-00932]\]. Although we have observed the patients for a longer period (5 years rather than 3 years), the current results and the post-hoc analyses of FREEDOM trial, which evaluated the effects of denosumab on aortic calcification progression in postmenopausal women \[[@B35-jcm-08-00932]\], did not reveal the potential benefits of denosumab in protecting against cardiovascular morbidity in both real-world practice and trial settings.

Our study, as others' studies \[[@B20-jcm-08-00932],[@B36-jcm-08-00932]\], showed that patients treated with denosumab exhibited better medication adherence than patients treated with alendronate. In the stratified analysis, patients with MPR ≥60% treated with denosumab revealed protective effect against CVD development, compared with those treated with alendronate. In the FREEDOM trial, 76% finished the complete injection \[[@B18-jcm-08-00932]\], whereas in a study by Samelson et al. \[[@B35-jcm-08-00932]\], 2363 of patients with CVD risk score \>4 and received at least one dose of denosumab were included. The protective effects of denosumab against CVD may become more significant only when the patients show higher adherence to denosumab. These findings are applicable to clinical practice. However, there is insufficient evidence to conclude that a patient adhered better to anti-resorptive therapy would has better adherence to their concomitant medications in terms of intensity or continuation during the study period. Owing to data limitation, our study did not obtain direct or indirect evidence of improved vascular calcification by X-ray or pulse wave velocity. Future studies investigating the pathophysiology of denosumab on cardiovascular events should be conducted.

There is little information regarding the effect of renal function in patients treated with denosumab, even in previous large randomized control trials of denosumab \[[@B18-jcm-08-00932],[@B19-jcm-08-00932],[@B20-jcm-08-00932]\]. Because denosumab is not eliminated through the kidney \[[@B37-jcm-08-00932],[@B38-jcm-08-00932]\], it is possible that scheduled renal monitoring for denosumab use was not considered in previous clinical trials. Two sequential studies of the FREEDOM trial showed no significant association between denosumab and worsening of eGFR and increased risk of CVD \[[@B35-jcm-08-00932],[@B39-jcm-08-00932]\].

It is worth noticing that alendronate is not recommended in patients with creatinine clearance (CrCl) less than 35 mL/min \[[@B40-jcm-08-00932]\], whereas denosumab is not restricted to patients with CKD. Recent systemic review and meta-analysis have demonstrated that denosumab increases bone mineral density and reduces fracture in renal transplant patients \[[@B41-jcm-08-00932]\]. However, the safety of denosumab in CKD patients remains unclear \[[@B42-jcm-08-00932]\]. In the present study, we also found that patients with renal diseases and ESRD were more in the denosumab than the alendronate group before PSM. In the matched cohort, baseline distribution of renal diseases was well balanced between treatment groups, study results showed that denosumab was associated with increased risk of worsening renal outcomes in the group of denosumab initiators with baseline eGFR \<60 mL/min/1.73 m^2^. These study findings bridge the knowledge gap and will enhance the awareness of the importance of renal monitoring in denosumab users. Although proteinuria and nephrotoxic medications (e.g., analgesics) were not all included in the analysis, they are relevant to renal function deterioration and should be regularly monitored in patients (e.g., diabetes, eGFR \<60, male patients) who are at risk of a rapid decline in eGFR.

Some studies showed inconsistent findings in renal outcomes between denosumab and other anti-resorptive treatments. A study reported that renal function was improved in patients with bone metastases by changing bone-modifying agent from zoledronic acid to denosumab \[[@B43-jcm-08-00932]\]. Other randomized phase III studies in patients with multiple myeloma or bone metastasis revealed 5%--15% of adverse renal outcomes in denosumab and zoledronate treatments \[[@B44-jcm-08-00932],[@B45-jcm-08-00932]\]; however, the definition of renal adverse events and whether the renal adverse events were attributed to chemotherapy or anti-resorptive therapy were not well explained.

Choosing proper control may be an important issue in identifying whether denosumab has renal benefits or not. It has been suggested that intravenous high-dose bisphosphonates, such as pamidronate or zoledronate, show higher renal toxicity than oral bisphosphonates \[[@B46-jcm-08-00932],[@B47-jcm-08-00932]\]. In contrast, a review article pointed out that alendronate has no negative effect on renal function, including in patients with eGFR of as low as 15 mL/min/1.73 m^2^ \[[@B48-jcm-08-00932]\]. Hence, it may be more reasonable to compare denosumab with alendronate. Taken together, despite its effectiveness in treating osteoporosis, denosumab should be used with caution, especially in male patients and in patients with AKI or renal insufficiency. Well-designed future studies exploring the effects denosumab on renal function in a specific population are necessary.

To our knowledge, this study is by far the largest-sized cohort study with over 5-year of follow-up for head-to-head comparison of denosumab and alendronate in patients with osteoporosis. This study allowed us to detect small differences in cardiovascular morbidity and renal outcomes between denosumab and alendronate treatments. The new user cohort design with PSM to account for confounding by indication is an important method to minimize bias. However, there was a possibility of unconsidered or unmeasured residual confounding, including smoking, alcohol, and body mass index as in many observational studies. Bone mineral density and bone turnover markers have not been available in the study setting. Moreover, because laboratory results, such as 1,25(OH)~2~ vitamin D and parathyroid hormone, are not part of routine care nor health insurance reimbursed tests in the study setting, our opportunity to evaluate the association between anti-resorptive therapy and vascular calcification and renal function was limited in this study. Lastly, the study individuals were derived from academic medical centers, and these findings might not be suitable for generalization to other settings having patients with less comorbid conditions. However, results of the current study raised intriguing questions worthy of additional investigation, such as the specific mechanisms of the cardiovascular protection of denosumab and their associations with renal function progression.

5. Conclusions {#sec5-jcm-08-00932}
==============

In this large cohort study, new denosumab users showed similar cardiovascular events as those of new alendronate users. However, in patients with adherence of ≥60% to MRP, denosumab treatment, compared with alendronate treatment, may result in significantly reduced risk of major cardiovascular events. With the popularity of denosumab use as an osteoporosis treatment in clinical practice settings, renal function status should be monitored regularly over treatment period, especially in male patients and in those with renal insufficiency at baseline.
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![Study flowchart. Propensity score was calculated based on baseline comorbidities: Peripheral vascular diseases, dementia, pulmonary disease, connective tissue disorder, peptic ulcer, liver diseases, diabetes, diabetes complications, paraplegia, renal disease, severe liver diseases, metastatic cancer, hypertension, hyperlipidemia, abnormal thyroid function, obstructive sleep apnea and fracture, and prior medication uses (oral anticoagulants, antiplatelets, aspirin, statins, fibrates, other lipid-lowering agents, antidiabetics, angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers(ARBs)/Aliskiren, diuretics, bisphosphonates, raloxifene, forteo, and calcitonin preparations). CABG: Coronary artery bypass surgery; ESRD: End stage renal disease; eGFR: Estimated glomerular filtration rate; MI: Myocardial infarction; PCI: Percutaneous coronary intervention.](jcm-08-00932-g001){#jcm-08-00932-f001}

![Cumulative incidence of composite cardiovascular outcomes between the denosumab and alendronate groups: All patients (**a**); patients with MPR ≥60% (**b**); patients with MPR \<60% (**c**); MPR: medication possession rate.](jcm-08-00932-g002){#jcm-08-00932-f002}

###### 

Cumulative incidence of eGFR decline ≥30% between the denosumab and alendronate groups: All patients (**a**); patients with eGFR\<60 mL/min/1.73 m^2^ at baseline (**b**); patients with eGFR ≥60 mL/min/1.73 m^2^ at baseline (**c**); eGFR: estimated glomerular filtration rate.
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![Stratified analyses of the risk of eGFR decline ≥30% between the denosumab and alendronate groups (denosumab versus alendronate). AKI: acute kidney injury; AHR: adjusted hazard ratio; eGFR: estimated glomerular filtration rate; MPR: medication possession rate. \# Adjusted for age group, sex, baseline eGFR group, mean dose of drug, CVD-related comorbidities, baseline comorbidities (abnormal thyroid function, obstructive sleep apnea, and fracture), concomitant medications (anti-thrombotic agents, lipid-lowering agents, antidiabetics, antihypertensive agents, and other osteoporosis therapy).](jcm-08-00932-g004){#jcm-08-00932-f004}
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###### 

Patient characteristics before and after matching.

  -------------------------------------------------------------------------------------------------------------------------------------------------
                                      Before PSM   After PSM                                                                                 
  ----------------------------------- ------------ ----------- --------- ------- --------- ------ ------ ------- --------- ------- --------- ------
  **Age at the index date, years**\   16,419       72.98       ±9.87     68.72   ±12.33    0.38   5046   71.59   ±10.13    71.22   ±10.23    0.04
  Mean ± SD                                                                                                                                  

  **Sex**                                                                                                                                    

   Male                               3377         486         (13.74)   2891    (22.44)   0.23   841    439     (17.40)   402     (15.93)   0.04

   Female                             13,042       3050        (86.26)   9992    (77.56)   0.23   4205   2084    (82.60)   2121    (84.07)   0.04

  **Baseline eGFR**\                  16,419       72.13       (30.57)   77.01   (26.47)   0.17   5046   78.35   (29.65)   78.77   (26.29)   0.01
  Mean ± SD                                                                                                                                  

  **Baseline comorbid conditions**                                                                                                           

   Peripheral vascular diseases       237          71          (2.01)    166     (1.29)    0.06   90     47      (1.86)    43      (1.70)    0.01

   Dementia                           642          206         (5.83)    436     (3.38)    0.12   224    110     (4.36)    114     (4.52)    0.01

   Pulmonary disease                  1903         435         (12.30)   1468    (11.39)   0.03   575    292     (11.57)   283     (11.22)   0.01

   Connective tissue disorder         711          167         (4.72)    544     (4.22)    0.02   260    123     (4.88)    137     (5.43)    0.03

   Peptic ulcer                       2917         746         (21.10)   2171    (16.85)   0.11   992    489     (19.38)   503     (19.94)   0.01

   Liver diseases                     1981         496         (14.03)   1485    (11.53)   0.07   710    353     (13.99)   357     (14.15)   0.00

   Diabetes                           3738         963         (27.23)   2775    (21.54)   0.13   1188   588     (23.31)   600     (23.78)   0.01

   Diabetes complications             968          298         (8.43)    670     (5.20)    0.13   374    182     (7.21)    192     (7.61)    0.02

   Paraplegia                         142          20          (0.57)    122     (0.95)    0.04   40     19      (0.75)    21      (0.83)    0.01

   Renal disease                      1158         531         (15.02)   627     (4.87)    0.34   443    231     (9.16)    212     (8.40)    0.03

   Severe liver diseases              82           24          (0.68)    58      (0.45)    0.03   25     13      (0.52)    12      (0.48)    0.01

   Metastatic cancer                  14           2           (0.06)    12      (0.09)    0.01   3      2       (0.08)    1       (0.04)    0.02

   Hypertension                       7195         1867        (52.80)   5328    (41.36)   0.23   2388   1208    (47.88)   1180    (46.77)   0.02

   Hyperlipidemia                     3849         1078        (30.49)   2771    (21.51)   0.21   1428   718     (28.46)   710     (28.14)   0.01

   Thyroid function abnormal          280          96          (2.71)    184     (1.43)    0.09   108    53      (2.10)    55      (2.18)    0.01

   Obstructive sleep apnea            131          84          (2.38)    47      (0.36)    0.17   98     55      (2.18)    43      (1.70)    0.03

   Fracture                           5871         1358        (38.40)   4513    (35.03)   0.07   1707   865     (34.28)   842     (33.37)   0.02

  **Prior medications**                                                                                                                      

   Oral anticoagulants                247          85          (2.40)    162     (1.26)    0.09   118    59      (2.34)    59      (2.34)    0.00

   Anti-platelet agents               2623         584         (16.52)   2039    (15.83)   0.02   792    404     (16.01)   388     (15.38)   0.02

   Aspirin                            2033         447         (12.64)   1586    (12.31)   0.01   626    318     (12.60)   308     (12.21)   0.01

   Statins                            2825         843         (23.84)   1982    (15.38)   0.21   1094   551     (21.84)   543     (21.52)   0.01

   Fibrates                           355          83          (2.35)    272     (2.11)    0.02   110    61      (2.42)    49      (1.94)    0.03

   Other lipid-lowering agents        68           17          (0.48)    51      (0.40)    0.01   24     12      (0.48)    12      (0.48)    0.00

   Anti-diabetic agents               3072         768         (21.72)   2304    (17.88)   0.10   1000   490     (19.42)   510     (20.21)   0.02

   ACEI/ARB/Aliskiren                 4293         1170        (33.09)   3123    (24.24)   0.20   1533   773     (30.64)   760     (30.12)   0.01

   Diuretics                          800          151         (4.27)    649     (5.04)    0.04   194    99      (3.92)    95      (3.77)    0.01

   Bisphosphonates                    18           4           (0.11)    14      (0.11)    0.00   5      2       (0.08)    3       (0.12)    0.01

   Raloxifene                         558          188         (5.32)    370     (2.87)    0.12   178    97      (3.84)    81      (3.21)    0.03

   Teriparatide                       186          71          (2.01)    115     (0.89)    0.09   74     36      (1.43)    38      (1.51)    0.01

   Calcitonin preparations            368          22          (0.62)    346     (2.69)    0.16   40     20      (0.79)    20      (0.79)    0.00

  **Year of index date**                                                                                                                     

   2012                               1463         324         (9.16)    1139    (8.84)    0.01   608    314     (12.45)   294     (11.65)   0.02

   2013                               1446         628         (17.76)   818     (6.35)    0.36   1065   526     (20.85)   539     (21.36)   0.01

   2014                               1342         686         (19.40)   656     (5.09)    0.45   1008   493     (19.54)   515     (20.41)   0.02

   2015                               1458         786         (22.23)   672     (5.22)    0.51   1126   567     (22.47)   559     (22.16)   0.01

   2016                               1077         634         (17.93)   443     (3.44)    0.48   789    397     (15.74)   392     (15.54)   0.01

   2017                               710          478         (13.52)   232     (1.80)    0.45   450    226     (8.96)    224     (8.88)    0.00
  -------------------------------------------------------------------------------------------------------------------------------------------------

ACEI: angiotensin converting enzyme inhibitors; ARBs: angiotensin receptor blockers; eGFR: estimated glomerular filtration rate; PSM: propensity score match; SMD: standardized mean difference.
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###### 

Cardiovascular adverse outcomes in the denosumab and alendronate groups.

                                  Denosumab        Alendronate      *p-*Value                  
  ------------------------------- ---------------- ---------------- ----------- -------------- ------------
  **Overall**                     ***n* = 2523**   ***n* = 2523**                              
   **Any CVD, n (%)**             **201**          **(7.97)**       **170**     **(6.74)**     **0.0945**
   Myocardial infarction          26               (1.03)           25          (0.99)         0.8881
   Ischemic stroke                131              (5.19)           113         (4.48)         0.2375
   Congestive heart failure       75               (2.97)           55          (2.18)         0.0755
   **Time to event, years**                                                                    
   Mean ± SD                      1.57             ±1.23            1.58        ±1.21          
   Median (25th, 75th)            1.31             (0.54, 2.40)     1.31        (0.65, 1.31)   
   **MPR of treatment ≥60%**      ***n* = 1608**   ***n* = 660**                               
   **Any CVD, n (%)**             **146**          **(9.08)**       **68**      **(10.30)**    **0.3653**
   Myocardial infarction          16               (1.00)           11          (1.67)         0.1804
   Ischemic stroke                94               (5.85)           46          (6.97)         0.3124
   Congestive heart failure       59               (3.67)           23          (3.48)         0.8309
   **Time to event, years**                                                                    
   Mean ± SD                      1.29             ±1.14            1.01        ±1.01          
   Median (25th, 75th)            0.99             (0.38, 1.77)     0.77        (0.20, 1.49)   
   **MPR of medications \<60%**   ***n* = 915**    ***n* = 1863**                              
   **Any CVD, n (%)**             **55**           **(6.01)**       **102**     **(5.48)**     **0.5654**
   Myocardial infarction          10               (1.09)           14          (0.75)         0.3608
   Ischemic stroke                37               (4.04)           67          (3.60)         0.5594
   Congestive heart failure       16               (1.75)           32          (1.72)         0.9530
   **Time to event, years**                                                                    
   Mean ± SD                      2.31             ±1.14            1.96        ±1.19          
   Median (25th, 75th)            2.48             (1.46, 3.01)     1.90        (1.02, 2.69)   

CVD: cardiovascular disease; MPR: medication possession rate.
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###### 

Factors associated with risk of composite outcome of cardiovascular disease.

  Variables                             Overall   MPR of Medications ≥60% ^\#^   MPR of Medications \<60%                                                           
  ------------------------------------- --------- ------------------------------ -------------------------- ------ -------------- ---------- ------ --------------- ----------
  **Denosumab (vs. Alendronate)**       1.03      (0.84, 1.26)                   0.8071                     0.74   (0.55, 1.00)   0.0493     1.04   (0.73, 1.50)    0.8178
  **Median dose of treatment**                                                                                                                                      
   ≥ median dose (vs. \< median dose)   2.37      (1.91, 2.93)                   \<0.0001                   2.59   (1.57, 4.26)   0.0002     1.65   (1.11, 2.45)    0.0130
  **Age group**                                                                                                                                                     
   ≥65 (vs. \<65) years                 2.84      (1.93, 4.16)                   \<0.0001                   2.92   (1.76, 4.86)   \<0.0001   2.75   (1.54, 4.92)    0.0006
  **Sex**                                                                                                                                                           
   Male (vs. Female)                    1.31      (1.00, 1.71)                   0.0479                     1.15   (0.81, 1.64)   0.4281     1.40   (0.94, 2.10)    0.0984
  **Baseline eGFR group**                                                                                                                                           
   \<60 (vs. ≥60) mL/min/1.73 m^2^      1.77      (1.43, 2.20)                   \<0.0001                   1.74   (1.31, 2.32)   0.0001     1.83   (1.32, 2.53)    0.0003
  **CVD-related risks** \*                                                                                                                                          
   1--2 (vs. 0)                         1.92      (1.42, 2.58)                   \<0.0001                   1.81   (1.23, 2.64)   0.0024     2.12   (1.31, 3.44)    0.0023
   ≥3 (vs. 0)                           1.99      (1.38, 2.86)                   0.0002                     2.09   (1.29, 3.39)   0.0027     1.94   (1.09, 3.46)    0.0249
  **Baseline comorbidities**                                                                                                                                        
   Thyroid function abnormal            0.85      (0.38, 1.93)                   0.7038                     0.28   (0.04, 2.03)   0.2087     1.43   (0.58, 3.53)    0.4447
   Obstructive sleep apnea              2.12      (0.93, 4.83)                   0.0737                     1.54   (0.56, 4.20)   0.4015     4.20   (1.00, 17.71)   0.0503
   Fracture                             1.32      (1.07, 1.62)                   0.0100                     1.26   (0.96, 1.67)   0.0985     1.44   (1.05, 1.98)    0.0245
  **Concomitant medications**                                                                                                                                       
   Anti-thrombotic agents               1.69      (1.34, 2.12)                   \<0.0001                   1.46   (1.07, 1.99)   0.0172     2.04   (1.45, 2.87)    \<0.0001
   Lipid-lowering agents                0.63      (0.49, 0.81)                   0.0003                     0.55   (0.39, 0.77)   0.0006     0.76   (0.52, 1.11)    0.1521
   Anti-diabetic agents                 1.37      (1.05, 1.79)                   0.0191                     1.16   (0.80, 1.68)   0.4337     1.63   (1.10, 2.40)    0.0142
   Anti-hypertensive agents             0.74      (0.58, 0.95)                   0.0164                     0.64   (0.46, 0.89)   0.0072     0.87   (0.59, 1.27)    0.4623
   Other osteoporosis therapy           0.60      (0.37, 0.97)                   0.0366                     0.44   (0.16, 1.18)   0.1019     0.68   (0.39, 1.19)    0.1803

AHR: adjusted hazard ratio; CVD: cardiovascular disease; eGFR: estimated glomerular filtration rate; MPR: medication possession rate. \* CVD-related risks: sum of baseline comorbid conditions (diabetes, hypertension, hyperlipidemia) and use of prior medications (anti-thrombotic, lipid-lowering, antidiabetic, and antihypertensive agents). \# In patients with MPR ≥60%, AHR was 0.42 (95%CI, 0.18--0.97; *p* = 0.0415) for risk of myocardial infarction development (denosumab vs. alendronate); 0.72 (95%CI, 0.5--1.04; *p* = 0.0805) for ischemic stroke; and 0.74 (95%CI, 0.44--1.24; *p* = 0.2534) for congestive heart failure.
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###### 

Renal outcomes in the denosumab and alendronate groups during the follow-up period.

  --------------------------------------------------------------------------------------
                                     Denosumab\          Alendronate\        *p-*Value
                                     (*n* = 2523)        (*n* = 2523)        
  ---------------------------------- ------------------- ------------------- -----------
  **Decline in eGFR (per year),**                                            

   Mean ± SD                         -0.25 ± 30.91       1.46 ± 48.24        

   Median (25th, 75th)               0.71 (-3.41,4.90)   0.38 (−3.30,4.90)   

  **Decline of eGFR ≥ 30%**                                                  

   Event, n (%)                      302 (11.97)         257 (10.19)         0.0436

   Time to event, years, mean ± SD   2.42 ± 1.58         2.39 ± 1.58         0.7564

  **Occurrence of AKI**                                                      

   Even, n (%)                       96 (47.06)          51 (35.66)          0.0345

   Time to event, years, mean ± SD   2.42 ± 1.59         2.28 ± 1.42         0.5215
  --------------------------------------------------------------------------------------

AKI: acute kidney injury; eGFR: estimated glomerular filtration rate.
